Malaria Severe anaemia and severe malaria Paediatrics
Conditions
Interventions
Delivery strategy A
Delivery strategy B
Delivery strategy control
Sponsors
Institut de Recherche Clinique du Benin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Aged below 10 years of both sexes - Hospitalised with severe anaemia or severe malaria (Initially hospitalised with haemoglobin below 5.0 g/dl or PCV below 15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and the presence of microscopy or RDT confirmed Plasmodium infection)
Exclusion criteria
Exclusion criteria: - Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia) - Sickle cell anaemia/sickle cell disease - Body weight below 5 kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of children with incomplete adherence to 9 doses of PDMC by the end of week 14 post-discharge Adherence to the PDMC strategy: Proportion of children with incomplete adherence to 9 doses of PDMC (three courses of 3-day treatments 3x3=9) i.e. the number of children who do not receive the total of 9 doses of PDMC tablets by the end of week 14 after discharge out of the total sample size. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of children readmitted to hospital from all-cause and malaria-specific by the end of week 14 post-discharge Incidence of all-cause and malaria-specific readmissions by the end of week 14 after discharge, i.e. the number of children readmitted for malaria by the end of week 14 after discharge out of the total sample size.;Number of sick-child clinic visits from all-cause and malaria-specific by the end of week 14 post-discharge Proportion of all-cause and malaria-specific sick-child clinic visits by the end of week 14 after discharge, i.e. the number of children who visit the hospital for any cause or due to malaria by the end of week 14 after discharge out of the total of sample size.;Number of children who die within 14 weeks post-discharge Incidence of all-cause mortality of children by the end of week 14 after discharge, i.e. the number of children who die within 14 weeks of discharge out of the total sample size.;Number of serious adverse events following PDMC administration within 14 weeks post-discharge Safety of PDMC strategy: Proportion of serious adverse events occurring after discharge to 14 weeks post-discharge, i.e. the number of children presenting serious adverse events by the end of week 14 after discharge out of the total sample size.;Cost per Disability adjusted life years (DALY) averted for each intervention versus control arm DALYs will be determined at the individual level and calculated based on the standard method used by the 2010 Global Burden of Disease Study (and using disability weights and life expectancies at age of death from the most recent WHO life tables). The total number of DALYs will be calculated by adding the DALYs for each individual who receives the intervention/s. The cost per DALY averted for each intervention will be compared against published country-specific willingness-to-pay thresholds to assess cost-effectiveness;Stakeholder perceptions of the feasibility on the delivery strategy with adherence supports Health | — |
Countries
Benin
Contacts
Public ContactAchille Massougbodji
Director IRCB
Outcome results
None listed